Emerging evidence also suggests that HMGB1 contributes to resistance against monoclonal antibody–based immunotherapies, such as anti-CD31 treatment in neuroblastoma, where HMGB1-driven signaling undermines therapeutic efficacy [245]. This evidence concerns the gene HMGB1 and neuroblastoma.